United-Guardian Reports Strong Nine-Month Financial Results

HAUPPAUGE, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported today that net income for the first nine months of 2017 increased by 55% compared with the same period in 2016, with gross sales for the period increasing by 24%. Net income for the nine-month period was $2,828,907 ($0.62 per share) on sales of $10,068,868, compared with net income of $1,830,607 ($0.40 per share) on sales of $8,114,093 for the comparable period last year. While gross sales for the third quarter were down slightly from $3,567,565 to $3,304,489, net income for the quarter was up 21% from $900,135 ($0.20 per share) to $1,090,323 ($0.24 per share) due to lower overhead and production costs.

Ken Globus, United-Guardian’s President, stated, “The 55% increase in net income for the first nine months of the year was attributable primarily to a 48% increase in sales of our personal care products. Supplementing that increase was a 54% increase in sales of our new single-dose form of Renacidin®, our proprietary urological product, which was introduced to the market in the second quarter of 2016. We are continuing to develop new products for the personal care market, especially ingredients for the growing “natural” products market, and we are optimistic that we will be able to continue to increase sales of these products over the next few years. In addition, we expect to launch our new Renacidin web site in the next few months, which we hope will increase awareness and sales of the product in the coming years.” 

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

Contact: Robert S. Rubinger
Public Relations
(631) 273-0900                  


 2017     2016 
Gross sales$3,304,489 $3,567,565  $10,068,868 $8,114,093 
Sales allowances and returns  (126,697)    (109,932)    (329,937)   (254,719)
Net Sales 3,177,792  3,457,633   9,738,931  7,859,374 
Costs and expenses:             
Cost of sales 1,110,806  1,594,198   4,042,015  3,499,589 
Operating expenses 438,257  460,401   1,320,342  1,393,286 
Research and development   159,531    158,593     507,535    494,054 
Total costs and expenses 1,708,594  2,213,192   5,869,892  5,386,929 
Income from operations 1,469,198  1,244,441   3,869,039  2,472,445 
Investment income 114,250  64,644    239,918  190,862 
Income before provision for income taxes
 1,583,448  1,309,085   4,108,957  2,663,307 
Provision for income taxes   493,125    408,950   1,280,050    832,700 
Net Income$1,090,323 $  900,135  $2,828,907 $1,830,607 
Earnings per common share             
(Basic and Diluted)$0.24 $ 0.20  $ 0.62 $ 0.40 
Weighted average shares – basic and diluted  4,594,319  4,594,319    4,594,319

••• Additional financial information can be found at the company’s web site at www.u-g.com. •••

NOTE:   This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.